{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    5,
    7,
    8,
    9,
    10,
    11,
    19,
    20,
    21,
    23,
    24,
    25,
    26,
    27
  ],
  "modelUsed": "gpt-5.1",
  "studyDesignStructure": {
    "studyArms": [
      {
        "id": "arm_1",
        "name": "ALXN1840 Single-Arm",
        "type": {
          "code": "Experimental Arm",
          "codeSystem": "USDM",
          "decode": "Experimental Arm"
        },
        "instanceType": "StudyArm",
        "description": "Single-arm, open-label, repeat-dose administration of ALXN1840 initiated at 15 mg once daily for approximately 28 days, followed by intra-patient titration to 30 mg once daily on Day 29, with allowable dose modification between 15 mg every other day and 30 mg/day based on safety."
      }
    ],
    "studyCells": [
      {
        "id": "cell_1",
        "armId": "arm_1",
        "epochId": "epoch_1",
        "elementIds": [],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_2",
        "armId": "arm_1",
        "epochId": "epoch_2",
        "elementIds": [],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_3",
        "armId": "arm_1",
        "epochId": "epoch_3",
        "elementIds": [],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_4",
        "armId": "arm_1",
        "epochId": "epoch_4",
        "elementIds": [],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_5",
        "armId": "arm_1",
        "epochId": "epoch_5",
        "elementIds": [],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_6",
        "armId": "arm_1",
        "epochId": "epoch_6",
        "elementIds": [],
        "instanceType": "StudyCell"
      }
    ],
    "studyCohorts": [
      {
        "id": "cohort_1",
        "name": "Cohort 1: Treatment-experienced",
        "instanceType": "StudyCohort",
        "characteristic": "Participants with Wilson disease who have received Wilson disease therapy (standard of care therapies or ALXN1840) for more than 28 days prior to enrollment."
      },
      {
        "id": "cohort_2",
        "name": "Cohort 2: Treatment-naïve",
        "instanceType": "StudyCohort",
        "characteristic": "Participants with Wilson disease who have received Wilson disease therapy for 28 days or less prior to enrollment."
      }
    ],
    "summary": {
      "armCount": 1,
      "cellCount": 6,
      "cohortCount": 2
    },
    "studyDesign": {
      "id": "sd_1",
      "name": "Study Design",
      "instanceType": "InterventionalStudyDesign",
      "trialIntentTypes": [
        {
          "code": "Treatment",
          "codeSystem": "USDM",
          "decode": "Treatment"
        },
        {
          "code": "Basic Science",
          "codeSystem": "USDM",
          "decode": "Basic Science"
        }
      ],
      "trialType": {
        "code": "Interventional",
        "codeSystem": "USDM",
        "decode": "Interventional"
      },
      "blindingSchema": {
        "code": "Open Label",
        "codeSystem": "USDM",
        "decode": "Open Label"
      },
      "randomizationType": {
        "code": "Non-Randomized",
        "codeSystem": "USDM",
        "decode": "Non-Randomized"
      },
      "controlType": {
        "code": "No Treatment",
        "codeSystem": "USDM",
        "decode": "No Treatment"
      },
      "armIds": [
        "arm_1"
      ],
      "cohortIds": [
        "cohort_1",
        "cohort_2"
      ],
      "therapeuticAreas": [
        "Hepatology",
        "Genetic Disease"
      ]
    }
  },
  "rawResponse": {
    "studyDesign": {
      "type": "Interventional",
      "trialIntentTypes": [
        "Treatment",
        "Basic Science"
      ],
      "blinding": {
        "schema": "Open Label",
        "maskedRoles": []
      },
      "randomization": {
        "type": "Non-Randomized",
        "allocationRatio": null,
        "stratificationFactors": []
      },
      "controlType": "No Treatment",
      "therapeuticAreas": [
        "Hepatology",
        "Genetic Disease"
      ]
    },
    "arms": [
      {
        "name": "ALXN1840 Single-Arm",
        "type": "Experimental Arm",
        "description": "Single-arm, open-label, repeat-dose administration of ALXN1840 initiated at 15 mg once daily for approximately 28 days, followed by intra-patient titration to 30 mg once daily on Day 29, with allowable dose modification between 15 mg every other day and 30 mg/day based on safety."
      }
    ],
    "cohorts": [
      {
        "name": "Cohort 1: Treatment-experienced",
        "characteristic": "Participants with Wilson disease who have received Wilson disease therapy (standard of care therapies or ALXN1840) for more than 28 days prior to enrollment."
      },
      {
        "name": "Cohort 2: Treatment-naïve",
        "characteristic": "Participants with Wilson disease who have received Wilson disease therapy for 28 days or less prior to enrollment."
      }
    ],
    "epochs": [
      {
        "name": "Screening",
        "description": "Pre-enrollment evaluations to determine eligibility; participants check in to the clinical research unit on Day -8."
      },
      {
        "name": "Run-in / Baseline Diet Equilibration and Pretreatment Balance",
        "description": "Inpatient Period 1, Day -8 to Day -5: diet equilibration on copper/molybdenum-controlled diet (Day -7 through Day -5); Day -4 through Day -1: measurement of pretreatment copper and molybdenum balance with intake and output collections while off chelator therapy."
      },
      {
        "name": "Treatment Period 1 – ALXN1840 15 mg/day Accumulation",
        "description": "Day 1 to approximately Day 9: initiation of ALXN1840 at 15 mg once daily; intensive intake/output collections from Day 1 through Day 8; PK/PD sampling including 24-hour profiles on Day 1; participants remain inpatient until Day 9."
      },
      {
        "name": "Outpatient Period (on 15 mg/day)",
        "description": "Day 9 to Day 22/23: participants may be discharged from the clinical research unit and continue daily 15 mg ALXN1840 dosing as outpatients; outpatient period may be extended up to an additional 14 days with investigator approval; participants use SMS text messaging to confirm dosing."
      },
      {
        "name": "Treatment Period 2 – 15 mg/day Steady State and 30 mg/day Accumulation/Steady State",
        "description": "Inpatient Period 2, Day 23 to Day 40: participants reinitiate inpatient stay on Day 22 or 23; remain on copper/molybdenum-controlled diet; intake and output collections from Day 25 through Day 39 to assess copper and molybdenum balance at 15 mg/day steady state and after titration to 30 mg/day on Day 29; includes PK/PD 24‑hour profiles on Days 25, 29, and 39."
      },
      {
        "name": "End of Study / Discharge",
        "description": "Completion of Inpatient Period 2 by Day 40 with final assessments of safety, copper and molybdenum balance, and pharmacokinetics; end of study defined per protocol (not fully detailed in excerpt)."
      }
    ]
  }
}